Search

Your search keyword '"Blanck, O"' showing total 49 results
Start Over Author "Blanck, O" Publisher elsevier b.v.
49 results on '"Blanck, O"'

1. Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy

Author

Klement, R.J., Hoerner-Rieber, J., Adebahr, S., Andratschke, N., Blanck, O., Boda-Heggemann, J., Duma, M., Eble, M.J., Eich, H.C., Flentje, M., Gerum, S., Hass, P., Henkenberens, C., Hildebrandt, G., Imhoff, D., Kahl, K.H., Klass, N.D., Krempien, R., Lohaus, F., Petersen, C., Schrade, E., Wendt, T.G., Wittig, A., and Guckenberger, M.

Published
2018
Full Text
View/download PDF

3. Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease

Author

Tanadini-Lang, S., Rieber, J., Filippi, A.R., Fode, M.M., Streblow, J., Adebahr, S., Andratschke, N., Blanck, O., Boda-Heggemann, J., Duma, M., Eble, M.J., Ernst, I., Flentje, M., Gerum, S., Hass, P., Henkenberens, C., Hildebrandt, G., Imhoff, D., Kahl, H., Klass, N.D., Krempien, R., Lohaus, F., Petersen, C., Schrade, E., Wendt, T.G., Wittig, A., Høyer, M., Ricardi, U., Sterzing, F., and Guckenberger, M.

Published
2017
Full Text
View/download PDF

7. PD-0174 Radiomics-based prediction of local control of brain metastases after resection and radiotherapy

Author

Buchner, J.A., Kofler, F., Mayinger, M., Christ, S.M., Brunner, T.B., Wittig, A., Menze, B., Zimmer, C., Meyer, B., Guckenberger, M., Andratschke, N., El Shafie, R.A., Debus, J., Rogers, S., Riesterer, O., Schulze, K., Feldmann, H.J., Blanck, O., Zamboglou, C., Ferentinos, K., Wolff, R., Eitz, K.A., Combs, S.E., Bernhardt, D., Wiestler, B., and Peeken, J.C.

Published
2023
Full Text
View/download PDF

8. PD-0064 Metastases-directed SRT combined with systemic therapy: 2y results of the TOaSTT real-world database

Author

Kroeze, S., Schaule, J., Spaas, M., Kahl, K.H., Verhoeff, J.J., Schneiders, F.L., Blanck, O., Lohaus, F., Rogers, S., Kaul, D., Benavente, S., Combs, S.E., Skazikis, G., Baumann, K., Popp, I., Koppe, F., Geinitz, H., de Jaeger, K.E., Siva, S., Stera, S., Wittig-Sauerwein, A., Lewitzki, V., Eckert, F., Schymalla, M.M., and Guckenberger, M.

Published
2023
Full Text
View/download PDF

19. PO-0811 SBRT compared to sorafenib in locally advanced hepatocellular carcinoma: a propensity score analysis

Author

Gkika, E., Brunner, T., Abbasi-Senger, N., Alheit, H., Baus, W., Blanck, O., Gerum, S., Guckenberger, M., Habermehl, D., Ostheimer, C., Riesterer, O., Tamihardja, J., Pinato, D.J., Rimassa, L., Pressiani, T., Schultheiss, M., Sharma, R., Burlone, M.E., Pirisi, M., Kudo, M., Park, J.W., Neumann-Haefelin, C., Grosu, A., Thimme, R., and Bettinger, D.

Published
2019
Full Text
View/download PDF

27. PV-0044: Repeat sbrt for pulmonary oligo-metastases

Author

Guckenberger, M., Klement, R., Rieber, J., Adebahr, S., Andratschke, N., Blanck, O., Boda-Heggemann, J., Duma, M., Eble, M.J., Eich, H.T., Flentje, M., Gerum, S., Haas, P., Henkenberens, C., Hildebrandt, G., Imhoff, D., Kahl, H., Klass, N.D., Krempien, R., Lohaus, F., Petersen, C., Schrade, E., Wendt, T.G., and Wittig, A.

Published
2018
Full Text
View/download PDF

40. General and Organ Specific Consensus Recommendations for Stereotactic Body Radiotherapy Dose Prescription according to ICRU Report 91 from Working Groups on Stereotactic Radiotherapy.

Author

Brunner, T.B., Boda-Heggemann, J., Buergy, D., Corradini, S., Dieckmann, U.K., Gerum, S., Gkika, E., Hoerner-Rieber, J., Kirste, S., Klement, R., Moustakis, C., Niyazi, M., Ruehle, A., Tanadini-Lang, S., Winkler, P., Zurl, B., and Blanck, O.

Subjects
*STEREOTACTIC radiotherapy, *EXPERIMENTAL design, *KIDNEY tumors, *ADRENAL tumors, *PHYSICIANS
Abstract

To develop expert recommendations for multiparametric dose prescriptions of SBRT according to ICRU report 91 to harmonize current SBRT practice and clinical trial design. Based on results of a working group literature summary a 2-tier Delphi-consensus process of 24 physician and physics experts from 3 European countries was conducted. Degree of consensus was predefined for overarching (OA) and organ specific (OS) statements (≥80%, 60-79%, <60% for high, intermediate and poor consensus). Post first round, statements were refined in a live discussion with 125 participants for the second round of the Delphi process. Experts consented on a total of 14 OA and 17 OS statements of SBRT of primary and secondary lung as well as liver, pancreas, adrenal and kidney tumors. Degree of consent was ≥80% in 79% and 41% of OA and OS statements, respectively, with higher consensus for lung compared to upper abdomen. In round 2, degree of consent ≥80% increased to 100% for OA and 88% in OS statements. No consensus was reached for dose escalation of liver metastases after chemotherapy (47%) and single fraction SBRT for kidney primaries (13%). In round 2, no statements had 60-79% consensus. In 29 of 31 statements a high consensus was achieved after a 2-tier Delphi process, and 1 statement (kidney) was clearly refused. The Delphi process was able to achieve a high degree of consensus for dose prescription of SBRT. In summary, clear recommendations for both OA and OS could be defined. This contributes significantly to harmonization and for the design of clinical trials in SBRT. Specific exemplary cases will be deducted from the statements in the next step. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. Post-Operative Stereotactic Radiotherapy for Resected Brain Metastases: Results of the Multicenter Analysis (AURORA) of the German Working Group "Stereotactic Radiotherapy".

Author

Bernhardt, D., Peeken, J.C., Kehl, V., Eitz, K., Guckenberger, M., Andratschke, N., Mayinger, M.C., Lindel, K., Dieckmann, K., El Shafie, R., Debus, J., Riesterer, O., Rogers, S., Blanck, O., Wolff, R., Grosu, A., Bilger, A., Henkenberens, C., Schulze, K., and Gani, C.

Subjects
*STEREOTACTIC radiotherapy, *RADIOTHERAPY, *KARNOFSKY Performance Status, *STEREOTACTIC radiosurgery, *PROGNOSIS, *OVERALL survival, *RADIATION injuries
Abstract

While the results of prospective studies support the use of postoperative stereotactic radiotherapy (RT) to the resection cavity (RC) as the standard of care after surgery, there are several issues that need to be investigated such as factors for improving local control, risk of leptomeningeal disease and radiation necrosis. Further, the optimal dose and fractionation is still under debate. The working group "Stereotactic Radiotherapy" of the German Society of Radiation Oncology (DEGRO) analyzed its multi-institutional database with 661 patients who received postoperative stereotactic RT to the RC. Treatment was performed at 13 centers between 2008 and 2021. Patient characteristics, treatment details, and follow-up data including overall survival (OS), local control (LC) were evaluated. Cox Regression and Kaplan-Meier curves with Log-rank Tests were calculated for selected variables. In this retrospective study, overall survival was 61.5% at 1 year, 47.6% at 2 years, and 35.5% at 3 years, and local control was 84.6% at 1 year, 74.8% at 2 years, and 72.8% at 3 years. 96% of patients were treated with hypofractionated stereotactic radiotherapy (HSRT), only 26 patients received single fraction radiosurgery (4%). Prognostic factors associated with overall survival were Karnofsky Performance Status, RPA and GPA class, controlled primary tumor and absence of extracranial metastases, whereas prognostic factor associated with local control was planning target volume (23 mL or less). HSRT is the most common fractionation form in the treatment of RCs in this multicenter analysis. This approach results in excellent OS and LC outcomes. OS in patients with resected brain metastases is mainly influenced by performance status. In regard to local control, RT of large cavities remain a challenge with significantly worse outcome. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

42. STereotactic Arrhythmia Radioablation: Critical Structure Contouring Benchmark Results of STOPSTORM.

Author

Balgobind, B., Visser, J., Grehn, M., Knap, M., de Ruysscher, D., Levis, M., Postema, P., Pruvot, E., Verhoeff, J., and Blanck, O.

Subjects
*ARRHYTHMIA, *VENTRICULAR tachycardia, *SPINAL canal, *IMAGING systems, *AORTA
Abstract

In patients with refractory ventricular tachycardia (VT), STereotactic Arrhythmia Radioablation (STAR) showed promising results for otherwise untreatable patients. The STOPSTORM.eu project coordinates European efforts to validate STAR. The primary goal of this critical structures benchmark study was to harmonize contouring of organs at risk (OARs) for STAR within the STOPSTORM.eu consortium. The results enable to refine protocols and guidelines to ensure treatment harmonization. Three STAR cases were selected for this benchmark study and sent to all radiation oncology centers within the consortium. Every case had a contrast-enhanced cardiac CT which was already deformed to the primary planning-CT to contour the OARs in detail. Every center was asked to contour 31 OARs according to literature-based guidelines. The resulting structure sets were qualitatively evaluated in an oncology imaging informatics system (technology company). For all structures and specific subset of structures the Dice coefficient (DICE) was calculated in a treatment planning system for all possible combinations of two centers. Twenty centers participated in the critical structure contouring benchmark. Contouring of the structures was performed with high accuracy according to the provided guidelines. The contours of common OARs, such as the heart, stomach, esophagus, bronchus, aorta and spinal canal in had a high conformity (median DICE resp. 0.92, 0.78, 0.71, 0.57, 0.87 and 0.71). In the substructures of the heart (chambers, valves, arteries, and nodes), deviations in the contours occurred more frequently. While the cardiac chambers had a high conformity value (median DICE of 0.84), the valves, arteries and nodes had lower values (median DICE of resp. 0.16, 0.31 and 0.26). However, these structures do not yet have a consensus for treatment planning purposes and late toxicity but need to be contoured correctly for future analysis within the STOPSTORM.eu project. This large and unique STOPSTORM.eu multi-center critical structures benchmark study showed a high accuracy regarding standard critical structures. For cardiac substructures some deviations occurred resulting in the development of new definitions for contouring these structures within the consortium. In addition, a close collaboration between radiation oncologist and cardiac electrophysiologist is warranted to reach optimal and effective STAR treatment. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

44. Stereotactic Arrhythmia Radioablation in Europe—Treatment Planning Benchmark Results of the STOPSTORM.eu Consortium.

Author

Trojani, V., Botti, A., Grehn, M., Balgobind, B., Savini, A., Pruvot, E., Verhoeff, J., Iori, M., and Blanck, O.

Subjects
*ARRHYTHMIA, *VENTRICULAR tachycardia, *STEREOTACTIC radiotherapy, *STEREOTAXIC techniques, *CORONARY arteries
Abstract

In patients with refractory ventricular tachycardia (VT), Stereotactic Arrhythmia Radioablation (STAR) showed promising results for otherwise untreatable patients. The STOPSTORM.eu project coordinates European efforts to clinically validate STAR and to refine protocols and guidelines. The aim of this work is to present the current clinical STAR practice in Europe based on three examples as baseline for further optimization. Target Volumes (TV) and Organs-at-Risk (OAR) were generated from previous consortium benchmarks and consensus definitions for three well-selected STAR cases. Planning Target Volumes (PTV) were generated based on three different compensation strategies for cardiac and respiratory motion and overlapped/close OARs like coronary arteries or stomach. The STOPSTORM.eu members were asked to generate single fraction treatment plans with 25 Gy dose prescription based on ICRU report 91 for each case based on their STAR clinical practice through multi-disciplinary discussion. Resulting dose distributions were analyzed independently using a customized platform for multi-center treatment planning studies. By November 2021, 20 centers submitted 22, 23 and 22 treatment plans for case 1, 2 and 3, respectively, mostly (75% of plans) using Intensity Modulated Arc Therapy (IMAT) with 6 MeV FFF beams (73% of the IMAT plans) among other commonly used techniques for stereotactic radiotherapy. Presently, used guidelines for STAR treatment planning and OAR dose limits vary greatly and are mostly based on the AAPM TG-101 report and RAVENTA trial publication. As a major finding, 73% of the submitted plans showed close OAR sparing overachieving high PTV coverage (Figure 1 and Table 1) arguing that lower doses may also result in clinical efficiency. Cases 1 and 3 dose distributions (referenced as A. and C. in Figure 2) highlighted how OARs sparing also resulted in heavy PTV under dosing for some participants. From this first STOPSTORM.eu multi-center/multi-platform treatment planning benchmark study we obtained important information concerning current clinical practice from major European centers performing Stereotactic Arrhythmia Radioablation for VT. With the strongly varying approaches of the centers as basis, the key task for the STOPSTORM.eu project is to find consensus, aiming to harmonize and optimize STAR practice in Europe. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

46. OC-0445: Patterns of care and outcome analysis of SBRT for liver metastases - a DEGRO database initiative.

Author

Andratschke, N., Alheid, H., Allgäuer, M., Becker, G., Blanck, O., Boda-Hegemann, J., Brunner, T., Combs, S., Duma, M., Gerum, S., Guckenberger, M., Hildebrandt, G., Ostheimer, C., Panje, C., Papachristofilou, A., Petersen, C., Schneider, T., Semrau, R., Wachter, S., and Habermehl, D.

Subjects
*LIVER metastasis, *STEREOTACTIC radiotherapy, *CANCER radiotherapy, *MEDICAL care, *ONCOLOGY, *MEDICAL research, *THERAPEUTICS
Published
2016
Full Text
View/download PDF

47. SBRT for Lung Metastases: A Pooled Analysis of 651 Patients and 868 Lesions of the German Working Group Stereotactic Radiotherapy.

Author

Sterzing, F., Streblow, J., Scherer, K., Adebahr, S., Adratschke, N., Boda-Heggemann, J., Blanck, O., Duma, M., Ernst, I., Gademann, G., Ganswindt, U., Henkenberens, C., Imhoff, D., Kahl, H., Lohaus, F., Lubinski-de Lange, G., Maertin, A., Petersen, C., Wittig, A., and Guckenberger, M.

Subjects
*LUNG cancer treatment, *METASTASIS, *STEREOTACTIC radiotherapy, *PATIENT selection, *MEDICAL quality control
Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results